Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Edessa vs YOURx Health

Edessa
Graded #115

Higher grade

vs+0.8
YOURx Health
Graded #126

Lower grade

The verdict

Edessa takes it — 70.8/100 to 70/100, but only just.

Edessa grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Clean three-rung tables one click in, behind a homepage whose three cards all quote six-month rungs and whose cheapest belongs to a different drug. YOURx Health is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueEdessa +1
68
67
Dose & formulationEdessa +5
80
75
Clinical oversightYOURx Health +6
74
80
Labs & monitoringYOURx Health +23
52
75
FulfillmentEdessa +29
84
55
Contract termsEdessa +9
64
55
Edessa · left barYOURx Health · right bar

The numbers

MetricEdessaYOURx Health
WeighScore70.8/10070/100
GradeCC
Scorecard rank#115#126
Semaglutide$179/mo month-to-month injectable ($135 only on a 6-month prepay)$179/mo (compounded)
Tirzepatide$239/mo month-to-month ($209 only on a 6-month prepay)$199/mo (compounded)
CoverageNot publicly listedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesYes
Edessa

Graded #115 · C

Strengths

  • Each product page carries a plain three-rung table, so the commitment behind every figure is visible
  • "Same price, every dose" is printed on each product page
  • Names its operating entity and a full street address in Las Vegas, Nevada
  • All-inclusive: provider consultation, medication, free expedited shipping, ongoing check-ins and 24/7 clinical support, and HSA and FSA eligible
  • An oral tablet sits beside the two injections

Where it loses points

  • The homepage leads with "Start for just $135", a six-month prepay on the semaglutide injection; month-to-month tirzepatide is $239
  • All three homepage cards quote the six-month rung, so the real monthly rates appear only after a click
  • Its Terms give two corporate forms for the same company in one clause — "Edessa Group, LLC, a Nevada corporation"
  • "Join 100,000+ successful GLP-1 patients" carries no source, and the money-back guarantee's terms are on no marketing page
  • No lab or monitoring protocol is published
YOURx Health

Graded #126 · C

Strengths

  • Lab monitoring included (per the home page) — most peer platforms gate labs as add-ons or skip them entirely
  • Physician video consultation with 'board-certified provider' disclosed
  • MD Integrations network is a recognized white-label clinical platform
  • Transparent published pricing: semaglutide injection $179/mo, tirzepatide injection $199/mo, oral RDT tablets $159-$179/mo

Where it loses points

  • Parent company / legal entity name NOT publicly disclosed — a material transparency gap for a health purchase
  • NO LegitScript / NABP / PCAB / BBB seal displayed — material trust-signal gap vs peer platforms
  • Per-state availability shown as 'Coverage 0 States' (placeholder metric) — appears the home page is incomplete or the platform is pre-launch
  • Pharmacy partners NOT publicly named
  • Too little is published about it to judge — treat this listing as provisional

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 544 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard